MedTrace Logo

Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19

NCT04348409 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-10-28

No results posted yet for this study

Summary

This is a proof of concept study to evaluate the efficacy of nitazoxanide (600 mg BID) to treat hospitalized patients with moderate COVID-19.

Conditions

Interventions

DRUG

Nitazoxanide Tablets

Patients will receive nitazoxanide 600 mg BID for 7 days

DRUG

Placebo

Patients will receive placebo BID for 7 days

Sponsors & Collaborators

  • Farmoquimica S.A.

    collaborator INDUSTRY

  • Hospital Vera Cruz

    collaborator OTHER

  • Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil

    collaborator UNKNOWN

  • Centro de Genomas - UNIFESP

    collaborator UNKNOWN

  • Emilio Ribas Institute of Infectious Diseases

    collaborator OTHER

  • Azidus Brasil

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-25
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04348409 on ClinicalTrials.gov